Lysosomal Storage Disease Treatment Market By Disease Type (Pompe Disease, Gaucher Disease, Fabry Disease, Mucopolysaccharidoses, Niemann-Pick Disease, Metachromatic Leukodystrophy, Acid Sphingomyelinase Deficiency, Krabbe Disease, Batten Disease, Others); By Treatment Type (Enzyme Replacement Therapy, Substrate Reduction Therapy, Pharmacological Chaperones, CNS-Targeted Biologics, Gene Therapy, Hematopoietic Stem Cell Transplantation, Supportive & Disease-Specific Therapies); By Route/Delivery Mode (Intravenous, Oral, Intracerebroventricular/Intrathecal, Ex Vivo Cell-Based Infusion); By Care Setting/Distribution Channel (Hospital & Outpatient Infusion Centers, Specialty Pharmacies, Home Infusion Services, Gene Therapy & Transplant Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Lysosomal Storage Disease Treatment Market: Newborn Screening, CNS Delivery, and Gene Therapy Reshape Rare-Disease Treatment

The Global Lysosomal Storage Disease Treatment Market was valued at USD 4.83 billion in 2025 and is projected to reach USD 6.94 billion by 2032, growing at a CAGR of 5.31%, according to Strategic Market Research.

 

Lysosomal storage diseases require a broad treatment approach. Key options include enzyme replacement, substrate reduction, chaperone medicines, CNS-targeted biologics, stem-cell transplantation, gene therapy, infusion support and specialist diagnostics across more than 50 inherited metabolic disorders.

 

Collectively, lysosomal storage diseases occur in approximately 1 in 7,000 to 8,000 live births. The commercially treatable population is considerably smaller because many conditions still lack approved disease-modifying therapies. Product eligibility may also depend on genotype, phenotype, age, neurological involvement, organ damage, and the stage at which treatment begins.

 

A 2020 review identified 23 FDA-approved orphan drugs across 11 lysosomal storage diseases, primarily for Gaucher, Fabry, Pompe, cystinosis, and mucopolysaccharidoses. Approvals introduced since then for metachromatic leukodystrophy, Niemann-Pick disease type C, and neurological Hunter syndrome have expanded treatment into diseases and manifestations previously managed largely through supportive care.

 

Treated patient-years, scheduled infusions, active prescriptions, treatment persistence, and completed gene-therapy procedures provide more useful demand measures than headline disease incidence. Underdiagnosis, molecular eligibility, irreversible progression, payer authorization, and limited specialist-center access prevent many patients from entering treatment.

 

Recurring Enzyme Replacement Therapy Accounts for Most Treatment Spending

Enzyme replacement therapy remains the most established treatment pathway for Pompe, Fabry, Gaucher, acid sphingomyelinase deficiency, and several mucopolysaccharidoses. Many patients receive therapy for years or throughout life, creating recurring demand for biologic manufacturing, cold-chain distribution, infusion nursing, laboratory monitoring, and reimbursement support.

Sanofi reported €790 million in 2025 sales from Nexviazyme/Nexviadyme, representing growth of 21.4%, while Fabrazyme generated more than €1.0 billion. Xenpozyme sales reached €228 million, increasing 54.3%. Nexviazyme growth included patients switching from Myozyme/Lumizyme, allowing the newer product to expand even when the overall number of treated Pompe patients changed only gradually.

Treatment schedules create substantial infusion demand despite small patient populations. The French Pompe Registry included 210 adults with late-onset Pompe disease in 2022, of whom 177, or 84.3%, were receiving ERT. Biweekly administration creates approximately 26 scheduled infusions per continuously treated patient each year. Across 177 patients, the standard schedule represents a theoretical workload of 4,602 infusions before allowing for missed, postponed, or discontinued treatment.

Hunter syndrome requires an even more frequent schedule. A multinational Hunter Outcome Survey analysis included 639 male patients who had received idursulfase for at least six months. Weekly dosing can require up to 52 infusions per continuously treated patient-year, increasing the need for specialist centers, outpatient infusion capacity, nursing coordination, and qualified home-infusion providers.

 

ERT Holds an Estimated 66% Share

Enzyme replacement therapy accounted for approximately 66% of treatment revenue in 2025, supported by lifelong dosing and established Fabry, Pompe, Gaucher, and MPS products. Substrate-reduction and chaperone therapies represented 20%, while gene and cell therapies accounted for 6% despite their high value per patient. HSCT, supportive care, and other disease-specific treatments contributed the remaining 8%. The shares are internally modeled because no consolidated audited global treatment split is publicly available.

 

Pompe Disease Leads with an Estimated 24% Share

Pompe disease generated an estimated 24% of treatment revenue in 2025, reflecting multiple premium ERT options, lifelong treatment, and active switching between established and next-generation products. Gaucher disease accounted for approximately 21%, Fabry disease 20%, and mucopolysaccharidoses 18%. Other disorders, including NPC, metachromatic leukodystrophy, ASMD, Batten disease, cystinosis, and lysosomal acid lipase deficiency, represented 17%, with neurological medicines and one-time therapies increasing their contribution.

 

Infusion Providers Account for an Estimated 61% Share

Hospital and outpatient infusion centers captured an estimated 61% of treatment revenue, reflecting the dominance of intravenous ERT. Specialty pharmacies and home-infusion providers represented approximately 27%, supported by chronic oral therapies and the transfer of stable infusion patients away from hospitals. Gene-therapy and transplant centers accounted for the remaining 12%. Their patient volumes are limited, but stem-cell collection, conditioning, individualized manufacturing, hospitalization, infusion, and long-term surveillance create high spending per completed treatment.

 

Oral Therapies Expand Choice for Genetically Eligible Patients

Substrate-reduction therapies and pharmacological chaperones reduce dependence on repeated intravenous administration. Their addressable populations remain narrower than the overall disease population because eligibility may depend on subtype, age, enzyme function, genetic variants, metabolic status, contraindications, and payer requirements.

The International Collaborative Gaucher Group Registry contained 5,985 people with type 1 Gaucher disease as of January 2023. Among them, 872 adults had started eliglustat, while 469 met the additional requirements for the published effectiveness analysis. Active prescriptions and long-term persistence therefore provide better demand measures than total registry enrollment.

Galafold follows a similar precision-treatment model in Fabry disease. More than 2,000 patients were receiving Galafold by the end of 2022, but treatment is restricted to people with amenable genetic variants. Galafold generated $521.7 million in 2025, while the Pompe combination Pombiliti plus Opfolda produced $112.5 million, increasing 60%.

Oral administration can improve convenience and reduce infusion-related costs, but it does not remove specialist oversight or molecular testing. Prescribers must confirm genetic suitability, monitor organ involvement, assess adherence, and determine whether disease progression warrants a return to infused therapy.

 

Newborn Screening Widens the Diagnosed Population

Earlier diagnosis is critical in disorders where neurological, muscular, cardiac, or organ damage becomes irreversible before symptoms lead to specialist referral. Dried-blood-spot enzyme assays, tandem mass spectrometry, biomarker analysis, and molecular sequencing are shifting diagnosis from symptom-led investigation toward population screening.

During 2018–2020, U.S. newborn-screening programs tested 5,479,082 infants for Pompe disease and reported 309 cases. Over the same period, 5,121,441 infants were screened for MPS I, resulting in 71 reported cases. Screening expanded considerably from 2015–2017, when approximately 1.83 million infants were tested for Pompe disease and 965,027 for MPS I.

The New York State Newborn Screening Program processed 246,895 dried-blood-spot specimens from 206,728 newborns in 2024, including 40,001 repeat specimens. The program recorded nine Krabbe referrals, nine MPS I referrals, and ten Pompe referrals. Preliminary findings included two infantile-onset Krabbe cases, one MPS I case, and five possible late-onset Pompe cases.

Each screen-positive result can create several follow-up events: repeat dried-blood-spot analysis, leukocyte or plasma enzyme testing, biomarker assessment, molecular sequencing, parental testing, genetic counseling, and specialist monitoring. Newborn screening therefore expands laboratory and clinical demand even when treatment does not begin immediately.

Pseudodeficiency alleles, carrier status, uncertain genetic variants, and possible late-onset disease can require surveillance rather than immediate therapy. Patients confirmed before organ or neurological deterioration, however, may remain on treatment for longer and are more likely to satisfy early-stage eligibility criteria for advanced therapies.

 

CNS-Targeted Medicines Address Previously Untreated Neurological Disease

Systemic enzyme replacement therapies often have limited penetration across the blood-brain barrier. Neurological decline has consequently remained insufficiently treated in Niemann-Pick disease type C, neuronopathic Hunter syndrome, metachromatic leukodystrophy, Sanfilippo syndrome, Krabbe disease, and selected Gaucher phenotypes.

The FDA approved Miplyffa and Aqneursa for Niemann-Pick disease type C within four days in September 2024. Miplyffa became the first FDA-approved NPC treatment and is administered with miglustat for neurological manifestations in adults and children aged two years and older.

Miplyffa generated $87.4 million in 2025, supported by 161 prescription-enrollment forms recorded since launch. Coverage reached 68% of U.S. covered lives, although formulary restrictions, prior authorization, dosing requirements, and continued clinical eligibility affect the number of patients who begin and remain on therapy.

Avlayah received accelerated FDA approval in March 2026 for neurological manifestations of Hunter syndrome in selected pediatric patients weighing at least five kilograms and treated before advanced neurological impairment. The engineered biologic is designed to carry enzyme activity into the central nervous system.

FDA review data reported a 91.4% mean reduction in cerebrospinal-fluid heparan sulfate at week 24. Continued approval remains dependent on confirmatory evidence of clinical benefit. Early diagnosis will influence uptake because patients with advanced neurological progression may no longer meet the indicated treatment stage.

Direct CNS administration is already established in CLN2 disease. Brineura is delivered into the cerebrospinal fluid through an implanted reservoir, creating demand for neurosurgical placement, repeated hospital administration, device maintenance, and specialist monitoring. Products that improve neurological delivery may create new treatment categories rather than simply compete with existing systemic ERT.

 

Gene Therapy Produces High Revenue per Patient but Limited Treatment Volume

Lenmeldy established a one-time gene-therapy pathway after its 2024 approval for selected children with early-onset metachromatic leukodystrophy. The evidence supporting approval included 37 treated children.

Treatment involves stem-cell mobilization, one or more apheresis procedures, patient-specific genetic modification, conditioning, infusion, and long-term monitoring. The therapy therefore generates several specialist treatment events even though the genetically modified cells are administered once.

Lenmeldy launched in the United States with a disclosed wholesale acquisition cost of $4.25 million. The initial commercial plan involved qualifying five specialized treatment centers and establishing outcomes-based payer arrangements. Treatment volumes remain dependent on early diagnosis, manufacturing capacity, hospital availability, payer authorization, travel requirements, and whether the child remains within the eligible disease stage.

The gene-therapy pipeline is extending into additional neurological LSDs. In April 2026, the FDA accepted Ultragenyx’s resubmitted application for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A, and assigned a September 19, 2026 action date. Approval would create the first disease-modifying commercial treatment for this neurodegenerative MPS subtype.

Hematopoietic stem-cell transplantation remains relevant in selected disorders where treatment before symptom onset may preserve neurological function. A U.S. pediatric hospital study identified 91 children with Krabbe disease, of whom 29, or 32%, received HSCT. Eligibility depends on disease stage, donor availability, transplant fitness, and access to an experienced center, keeping procedure volumes substantially below recurring ERT use.

 

North America Leads Recent Approvals, While International Uptake Depends on Funding

North America accounted for an estimated 45% of the global lysosomal storage disease treatment market in 2025, supported by a dense network of metabolic specialists, broad access to genetic testing, expanding newborn-screening programs, and faster commercialization of orphan medicines. Recent approvals for Lenmeldy, Miplyffa, Aqneursa, and Avlayah strengthened the region’s position in gene therapy, neurological treatment, and high-value rare-disease care. Revenue is concentrated in the United States, where high treatment prices, established specialty-pharmacy channels, and insurer-funded biologics support strong spending per diagnosed patient. Adoption remains uneven, however, because prior authorization, Medicaid variation, site-of-care restrictions, and the limited number of qualified advanced-therapy centers can delay treatment.

Europe represented an estimated 34% share in 2025, making it the second-largest regional market. Demand is supported by national rare-disease programs, established metabolic treatment centers, coordinated referral networks, and public reimbursement for long-term ERT and selected oral therapies. Revenue growth is more dependent on health technology assessment, negotiated discounts, and country-specific commissioning than in North America. Germany, France, Italy, Spain, and the Nordic countries provide relatively strong treatment access, while reimbursement decisions can differ sharply across national systems. Asia-Pacific and other regions accounted for the remaining 21%, with growth constrained by underdiagnosis, limited confirmatory testing, fewer specialist centers, and inconsistent funding for lifelong or one-time high-cost therapies. The regional shares are internally modeled.

 

Portfolio Consolidation Increases the Value of Established Patient Networks

Competition is concentrated among companies with biologic manufacturing capacity, orphan-drug regulatory experience, specialist sales teams, and established payer relationships. Sanofi retains major positions across Pompe, Fabry, Gaucher, MPS, and ASMD, while Takeda and BioMarin remain important suppliers in established enzyme-replacement categories.

BioMarin completed its approximately $4.8 billion acquisition of Amicus Therapeutics in April 2026, adding Galafold for Fabry disease and Pombiliti plus Opfolda for Pompe disease.

The acquisition combines commercial teams, metabolic-center relationships, reimbursement infrastructure, patient-support programs, and manufacturing capabilities across two established rare-disease franchises. These assets can reduce launch costs and improve patient identification, treatment switching, and geographic expansion.

Smaller companies can secure valuable positions by introducing the first treatment for an untreated neurological manifestation. Zevra’s Miplyffa launch, Denali’s Avlayah approval, Orchard’s Lenmeldy commercialization, and Ultragenyx’s UX111 program demonstrate the commercial importance of CNS delivery, early intervention, and potentially durable genetic correction.

 

Earlier Diagnosis and Treatment Eligibility Will Shape Revenue Growth

Recurring ERT will continue to account for most spending because of lifelong dosing, high persistence, and established Fabry, Pompe, Gaucher, and MPS franchises. Oral therapies will expand where they reduce infusion burden or serve genetically defined populations. CNS-targeted biologics and gene therapies will create new revenue in disorders that previously lacked disease-modifying treatment.

Growth will depend on broader newborn screening, faster confirmatory testing, family cascade testing, earlier specialist referral, geographic launches, and payer acceptance. Delayed diagnosis, narrow molecular eligibility, treatment-stage restrictions, small clinical evidence populations, infusion burden, center capacity, confidential discounts, and switching-related cannibalization will continue to limit conversion of disease prevalence into treated demand.

 

Lysosomal Storage Disease (LSD) Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.83 Billion
Revenue Forecast in 2032	USD 6.94 Billion
Overall Growth Rate	CAGR of 5.31% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Disease Type, By Treatment Type, By Route/Delivery Mode, By Care Setting/Distribution Channel, By Geography
By Disease Type	Pompe Disease, Gaucher Disease, Fabry Disease, Mucopolysaccharidoses, Niemann-Pick Disease, Metachromatic Leukodystrophy, Acid Sphingomyelinase Deficiency, Krabbe Disease, Batten Disease, Others
By Treatment Type	Enzyme Replacement Therapy, Substrate Reduction Therapy, Pharmacological Chaperones, CNS-Targeted Biologics, Gene Therapy, Hematopoietic Stem Cell Transplantation, Supportive & Disease-Specific Therapies
By Route/Delivery Mode	Intravenous, Oral, Intracerebroventricular/Intrathecal, Ex Vivo Cell-Based Infusion
By Care Setting/Distribution Channel	Hospital & Outpatient Infusion Centers, Specialty Pharmacies, Home Infusion Services, Gene Therapy & Transplant Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Market Drivers	Expansion of newborn screening and molecular diagnostics Sustained demand for lifelong enzyme replacement therapy Rising availability of CNS-targeted medicines
Customization Option	Available upon request